An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma.

Abstract:

INTRODUCTION:Hepatocellular carcinoma (HCC) is a frequent and severe complication of cirrhosis. Most HCC patients initially present with or progress to advanced stage disease and require systemic treatment. As hypervascularization is a major characteristic of HCC, antiangiogenic drugs have been tested. Areas covered: In this review, we summarize data on the use of drugs targeting the angiogenesis. Despite many trials, in 2017 only 3 drugs, all antiangiogenic, have demonstrated efficacy in first (sorafenib, lenvatinib) or second line (regorafenib) treatment of advanced HCC. The heterogeneous mechanisms of action and the major reasons for failure of most trials are discussed. An English-language, abstract-based literature review was performed by a PubMed-based strategy. Expert opinion: Currently all trials based on purely antiangiogenic compounds (bevacizumab, linifanib, brivanib and ramucirumab) or drugs with strong antiangiogenic properties (sunitinib) have failed (increased toxicity, minor efficacy and/or flaws in trial design); sorafenib, lenvatinib and regorafenib are multityrosine kinase inhibitors and their efficacy can be partly related to another mechanism of action. We need to better refine future trials design (randomized phase 2, good stratification factors and marker-enriched patient selection) in order to progress toward customized treatment, perhaps in association with immunotherapy.

authors

Raoul JL,Gilabert M,Adhoute X,Edeline J

doi

10.1080/14656566.2017.1378346

subject

Has Abstract

pub_date

2017-10-01 00:00:00

pages

1467-1476

issue

14

eissn

1465-6566

issn

1744-7666

journal_volume

18

pub_type

杂志文章,评审
  • Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer.

    abstract:INTRODUCTION:Docetaxel and paclitaxel are among the most active agents for the treatment of breast cancer. These first-generation taxanes are extremely hydrophobic; therefore, solvents are needed for its parenteral administration. Albumin nanoparticle technology allows for the transportation of such hydrophobic drugs w...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.651127

    authors: Guarneri V,Dieci MV,Conte P

    更新日期:2012-02-01 00:00:00

  • Abacavir/lamividune combination in the treatment of HIV-1 infection: a review.

    abstract::Consensus guidelines for the management of HIV infection recommend the use of two nucleoside analogues in combination with either a non-nucleoside reverse transcriptase inhibitor or a ritonavir-boosted protease inhibitor in therapy-naive patients. As adherence is crucial for treatment success, regimens with fewer pill...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.18.2571

    authors: Waters L,Moyle G

    更新日期:2006-12-01 00:00:00

  • New antiviral agents for the treatment of hepatitis C: ABT-450.

    abstract:INTRODUCTION:Hepatitis C virus (HCV) therapy continues to evolve rapidly. ABT-450 is a novel potent inhibitor of the non-structural 3/4A protease that has been studied in combination with several agents, allowing shorter duration of therapy and interferon-free/ribavirin-free all-oral regimens. Preliminary data from stu...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.889116

    authors: Carrion AF,Gutierrez J,Martin P

    更新日期:2014-04-01 00:00:00

  • Effect of omega-3-acid ethyl esters on steady-state plasma pharmacokinetics of atorvastatin in healthy adults.

    abstract:BACKGROUND:Prescription omega-3-acid ethyl esters (P-OM3) have been used as adjunctive therapy to statin drugs in patients with mixed hyperlipidemia. OBJECTIVE:To assess the effect of concomitant administration of 4 g P-OM3 on the steady-state pharmacokinetics of the maximum recommended daily dose of atorvastatin (80 ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,随机对照试验

    doi:10.1517/14656560802233827

    authors: Di Spirito M,Morelli G,Doyle RT,Johnson J,McKenney J

    更新日期:2008-12-01 00:00:00

  • Anorexia in end-stage renal disease: pathophysiology and treatment.

    abstract::Anorexia is a frequent complication of uraemic syndrome, which contributes to malnutrition in dialysis patients. Uraemic anorexia has been associated with many factors. This paper reviews the current knowledge about mechanisms responsible for uraemic anorexia, the treatments and new drugs used to control the loss of a...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2.11.1825

    authors: Aguilera A,Selgas R,Diéz JJ,Bajo MA,Codoceo R,Alvarez V

    更新日期:2001-11-01 00:00:00

  • Emerging paradigms in targeted treatments for Asian patients with NSCLC.

    abstract:INTRODUCTION:EGFR-targeted drugs have been successfully approved in many countries and have demonstrated higher efficacy and lower toxicity than chemotherapy in molecularly defined subgroups of patients. Significant advances in clinical trials and studies focusing on targeted therapies have rapidly developed in Asia. ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1040391

    authors: Ke EE,Zhou Q,Wu YL

    更新日期:2015-06-01 00:00:00

  • Fixed combinations of dorzolamide-timolol and brimonidine-timolol in the management of glaucoma.

    abstract:IMPORTANCE OF THE FIELD:The emergence of fixed-combination drugs for the treatment of glaucoma has, to some extent, changed the medical management of glaucoma. The potential benefits of these drugs include a reduction in the total number of drops and preservatives instilled per day and improved patient comfort factors,...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656561003667540

    authors: Razeghinejad MR,Sawchyn AK,Katz LJ

    更新日期:2010-04-01 00:00:00

  • Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia.

    abstract:BACKGROUND:Moderate hypertriglyceridemia is fairly common, and elevated triglycerides are a risk factor for coronary heart disease. The omega-3 fatty acids EPA and DHA have been shown to lower triglycerides in many clinical studies. Prescription omega-3 fatty acid concentrates (P-OM3) are indicated for use in people wi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.7.1237

    authors: Skulas-Ray AC,West SG,Davidson MH,Kris-Etherton PM

    更新日期:2008-05-01 00:00:00

  • Chemotherapeutic inhibitors in the treatment of prostate cancer.

    abstract:INTRODUCTION:Prostate cancer being the second leading cause of death in men in Western countries remains a major challenge in healthcare. Several novel agents targeting signaling pathways in prostate cancer have recently been approved by the US Food and Drug Administration (FDA) but there is still an unmet need for new...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.852184

    authors: Deshmukh RR,Schmitt SM,Hwang C,Dou QP

    更新日期:2014-01-01 00:00:00

  • Erectile dysfunction, cardiovascular diseases and depression: interaction of therapy.

    abstract::Several studies have revealed the intimate associations between erectile dysfunction (ED), ischemic heart disease (IHD) and depression. Whether the physicians should also screen for the other two components when a patient presents with one component of this triad is still an important question to be answered. These th...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560903089326

    authors: El-Sakka AI,Shamloul R,Yassin AA

    更新日期:2009-09-01 00:00:00

  • Silodosin : a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia.

    abstract:INTRODUCTION:Silodosin is a new uroselective alpha-blocker with high pharmacological selectivity for the (1A) adrenoceptor. It is an effective and well-tolerated treatment in men with lower urinary tract symptoms (LUTS), due to presumed bladder outlet obstruction secondary to benign prostatic hyperplasia (BPH). The eff...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.714368

    authors: Osman NI,Chapple CR,Cruz F,Desgrandchamps F,Llorente C,Montorsi F

    更新日期:2012-10-01 00:00:00

  • Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies.

    abstract:INTRODUCTION:Immune-checkpoint inhibitor (ICPI) drugs, which include antibodies against CTLA-4, PD-1 and PD-L1, have been shown to induce durable complete responses in a proportion of patients with particular efficacy demonstrated in both the first line and refractory setting in advanced NSCLC and melanoma. However, th...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1369956

    authors: Flynn MJ,Larkin JMG

    更新日期:2017-10-01 00:00:00

  • Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs.

    abstract:BACKGROUND:Patients with rheumatoid arthritis (RA) have an increased risk of atherosclerotic cardiovascular disease which cannot be explained by traditional cardiovascular risk factors alone. Atherosclerosis is considered an inflammatory condition and inflammation experienced in RA may contribute to accelerated atheros...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.7.1121

    authors: Avouac J,Allanore Y

    更新日期:2008-05-01 00:00:00

  • Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression.

    abstract::Selective serotonin reuptake inhibitors (SSRIs) are now generally regarded as effective and better tolerated alternatives to tricyclic antidepressants (TCAs) for the treatment of depression. SSRIs also seem to be as well tolerated as moclobemide, mirtazapine, venlafaxine, reboxetine and nefazodone and show comparable ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.1.5.917

    authors: Mace S,Taylor D

    更新日期:2000-07-01 00:00:00

  • Pharmacotherapy of obstructive sleep apnea.

    abstract:INTRODUCTION:Obstructive sleep apnea syndrome is a common public health problem in the general population. The important health-related consequences of obstructive sleep apnea include cardiovascular disorders, such as myocardial infarction and hypertension, stroke, sudden death and difficult blood sugar control related...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.666525

    authors: Lin CM,Huang YS,Guilleminault C

    更新日期:2012-04-01 00:00:00

  • Evolving treatment strategies for chronic refractory angina.

    abstract::Chronic refractory angina is a term used to describe patients who, despite optimal medical therapy, have both angina and objective evidence of ischaemia. It is estimated that 5-15% of the 12 million patients with chronic angina in the US meet the criteria for having refractory angina. This review focuses on the follow...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.3.259

    authors: Yang EH,Barsness GW

    更新日期:2006-02-01 00:00:00

  • Therapeutic drug monitoring of mycophenolate mofetil and enteric-coated mycophenolate sodium in patients with systemic lupus erythematosus.

    abstract:OBJECTIVE:Mycophenolic acid (MPA), the active form of mycophenolate mofetil (MMF) and enteric-coated mycophenolate sodium (EC-MPS), is used to treat systemic lupus erythematosus (SLE). MMF and EC-MPS pharmacokinetics were examined to devise guidance for therapeutic drug monitoring (TDM) for SLE patients with normal ren...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656561003592144

    authors: Djabarouti S,Duffau P,Lazaro E,Chapouly C,Greib C,Viallard JF,Pellegrin JL,Saux MC,Breilh D

    更新日期:2010-04-01 00:00:00

  • Tolterodine extended-release for overactive bladder.

    abstract::Overactive bladder (OAB) is a common problem. Affected individuals suffer decreased quality of life and productivity. The mainstay of pharmacological treatment of OAB is antimuscarinic agents. Tolterodine was the first antimuscarinic drug designed specifically for treating OAB. Compared with the immediate-release (IR)...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560903167965

    authors: Chung DE,Te AE

    更新日期:2009-09-01 00:00:00

  • Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia.

    abstract::Hyperlipidaemia is a pivotal risk factor for the development of atherosclerotic disease. A large number of studies have demonstrated that the treatment of abnormalities in lipoprotein levels reduces the risk for myocardial infarction, peripheral vascular disease, carotid artery disease, stroke, and cardiovascular mort...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.1.131

    authors: Toth PP,Davidson MH

    更新日期:2005-01-01 00:00:00

  • Opioids in the treatment of postoperative pain: old drugs with new options?

    abstract::New approved options with opioids in the postoperative setting may include new ways of administration, new combinations with other drugs and new opioid drugs. Newly approved devices for administration include sublingual sufentanil dispenser and transdermal iontophoretic fentanyl, with the purpose of almost mimicking t...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 社论

    doi:10.1517/14656566.2014.879292

    authors: Raeder J

    更新日期:2014-03-01 00:00:00

  • Pharmacoeconomic considerations in anticoagulant drug use.

    abstract::Anticoagulants are used for the prevention and treatment of venous thromboembolism and for the secondary prevention of stroke and myocardial infarction. The list of available anticoagulants includes unfractionated heparin, low molecular weight heparins, fondaparinux, warfarin and the direct thrombin inhibitors. Numero...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.8.989

    authors: Hawkins D,Huston SA

    更新日期:2006-06-01 00:00:00

  • Pharmacological treatment of generalized anxiety disorder.

    abstract:INTRODUCTION:Generalized anxiety disorder (GAD) is a chronic, relapsing, debilitating disorder, associated with markedly impaired social and occupational functioning. Pharmacological treatment is considered standard care and several drug classes are now FDA approved for the treatment of GAD. While there are clear data ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.618496

    authors: Reinhold JA,Mandos LA,Rickels K,Lohoff FW

    更新日期:2011-11-01 00:00:00

  • Amifostine: chemotherapeutic and radiotherapeutic protective effects.

    abstract::Amifostine (Ethyoltrade mark, Alza Pharmaceuticals) is an inorganic thiophosphate cytoprotective agent known chemically as ethanethiol, 2-[3- aminopropyl)amino]dihydrogen phosphate. It is a prodrug of free thiol (WR-1065) that may act as a scavenger of free radicals generated in tissues exposed to cytotoxic drugs and ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2.3.479

    authors: Santini V

    更新日期:2001-03-01 00:00:00

  • Systemic retinoids in chemoprevention of non-melanoma skin cancer.

    abstract:BACKGROUND:The incidence of non-melanoma skin cancer is increasing worldwide. Systemic retinoids are useful for the chemoprophylaxis of non-melanoma skin cancers. Retinoids have pleiotropic effects, but their exact cancer chemopreventive mechanism is still not clear. OBJECTIVE:The aim of this study was to review publi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.8.1363

    authors: Lens M,Medenica L

    更新日期:2008-06-01 00:00:00

  • Efficacy of elagolix in the treatment of endometriosis.

    abstract:INTRODUCTION:Much research has gone into developing medications that can be used to alleviate endometriosis-associated symptoms. In addition to already established medications, a new GnRH antagonist, elagolix, is in development. The novelty of this drug compared to other GnRH antagonists, is its nonpeptide structure, a...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1359258

    authors: Perricos A,Wenzl R

    更新日期:2017-09-01 00:00:00

  • Asthma therapy during pregnancy.

    abstract::Numerous pregnant women suffer from asthma and the use of asthma medications during pregnancy may be a necessity. Although some information is known about the effects of asthma medications during pregnancy, there is still a significant amount of information to learn and particular attention is required when prescribin...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.7.1019

    authors: Demoly P,Piette V,Daures JP

    更新日期:2003-07-01 00:00:00

  • Treatment modalities for bacterial rhinosinusitis.

    abstract:IMPORTANCE OF THE FIELD:Rhinosinusitis is a common illness that represents a substantial economic burden. The vast majority of cases resolve spontaneously but a small proportion develops a secondary bacterial infection. Accurate diagnosis of rhinosinusitis depends upon clinical assessment. Isolation of the causative ag...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656561003598901

    authors: Brook I

    更新日期:2010-04-01 00:00:00

  • Imiquimod: an immune response modifier in the treatment of precancerous skin lesions and skin cancer.

    abstract::Actinic keratosis (AK) and basal cell carcinoma (BCC) are precancerous and cancerous skin lesions that should be treated especially when multiple or in cosmetically important areas. Apart from 5% 5-fluorouracil topical cream, which some feel is the gold standard topical treatment for AK, several invasive treatment mod...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.11.1743

    authors: Papadavid E,Stratigos AJ,Falagas ME

    更新日期:2007-08-01 00:00:00

  • A comparative evaluation of properties and clinical efficacy of the echinocandins.

    abstract::With the increase in prevalence of fungal infections, newer antifungal agents are needed to effectively treat invasive disease, and at the same time minimize adverse effects from therapy. The echinocandins comprise a novel class of antifungals; their mechanism of action involves inhibiting 1,3-beta-D-glucan synthase, ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.10.1479

    authors: Kim R,Khachikian D,Reboli AC

    更新日期:2007-07-01 00:00:00

  • Latest treatment strategies for membranous nephropathy.

    abstract::Thirty to forty percent of patients with idiopathic membranous nephropathy have persistent heavy proteinuria and may progress to end-stage kidney disease in 5 - 15 years. The ideal treatment for these patients is a matter of debate. Several nonspecific immunosuppressive regimens have been suggested with the aim of red...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.18.3159

    authors: Ruggenenti P,Cravedi P,Remuzzi G

    更新日期:2007-12-01 00:00:00